Evaluating the comparative risk of postoperative complications associated with infliximab and vedolizumab for patients with Crohn’s disease
Crossref DOI link: https://doi.org/10.30574/ijsra.2024.13.2.2109
Published Online: 2024-11-30
Update policy: https://doi.org/10.30574/ijsra.ourcrossmarkpolicy
Sultan Akbar,
